Article: Other News To Note.

Active Biotech AB, of Stockholm, Sweden, said its recent offering of SEK169 million (US$21.4 million) was oversubscribed by 43 percent, increasing the number of shares in the company to a total of 39.4 million. The first day of trading in the new shares will occur on or around July 25. Active Biotech focuses on drugs to treat autoimmune/inflammatory diseases and cancer.

BioSyntech Inc., of Laval, Quebec, signed a letter of intent for Nicholas Piramal India Ltd., of Mumbai, India, to subscribe to 7.5 million of its common shares at a price of C$0.80 (US$0.66) per share. NPIL's post-issue shareholding will be about 17 percent of BioSyntech's issued shares. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!